Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 6 mg/ml; calcium chloride dihydrate, quantity: 0.27 mg/ml; potassium chloride, quantity: 0.4 mg/ml; sodium lactate, quantity: 3.12 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. the solution may also be used as a solvent for intravenously administrated drugs where compatibility has been established. compound sodium lactate is particularly suitable for the replacement of extracellular fluid loss when isotonic dehydration is evident and in burn therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - calcium chloride dihydrate, quantity: 270 mg/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; sodium chloride, quantity: 6 g/l - injection, solution - excipient ingredients: sodium hydroxide; water for injections - is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are comparable with the solutions.

Australia - English - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 6.24 g/l; potassium chloride, quantity: 0.4 g/l; calcium chloride dihydrate, quantity: 0.27 g/l - injection, intravenous infusion - excipient ingredients: water for injections - for intravenous fluid therapy designed to correct deficiencies in hydration, electrolyte and energy levels. may also be used as a solvent for intravenously administered drugs where compatibility has been established. indications as at 22 august 2005 : compound sodium lactate solution is particularly suitable for replacement of extracellular fluid loss where isotonic dehydration is evident and in burn therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 400 mg/l; sodium lactate, quantity: 3.22 g/l; calcium chloride dihydrate, quantity: 270 mg/l; sodium chloride, quantity: 6 g/l - injection, solution - excipient ingredients: sodium hydroxide; lactic acid; water for injections - is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are comparable with the solutions. this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

United States - English - NLM (National Library of Medicine)

hospira, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid, unspecified form - unii:33x04xa5at), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0 - potassium chloride 1.79 g in 1000 ml - these solutions are indicated in patients requiring parenteral administration of potassium chloride and the replacement of extracellular losses of fluids and electrolytes with minimal carbohydrate calories. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. solutions containing lactate are not for use in the treatment of lactic acidosis. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw need

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 2.2 g/l; calcium chloride dihydrate, quantity: 270 mg/l - injection, solution - excipient ingredients: lactic acid; sodium hydroxide; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Malta - English - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - calcium chloride, dihydrate, potassium chloride, sodium chloride, sodium lactate - solution for infusion - calcium chloride dihydrate 0.27 g/l potassium chloride 0.4 g/l sodium chloride 6 g/l sodium lactate 3.2 g/l - blood substitutes and perfusion solutions

Malta - English - Medicines Authority

baxter healthcare limited - calcium chloride, dihydrate, potassium chloride, sodium chloride, sodium lactate - solution for infusion - calcium chloride dihydrate 0.27 gram(s)/litre ; potassium chloride 0.4 gram(s)/litre ; sodium chloride 6 gram(s)/litre ; sodium lactate 3.2 gram(s)/litre - blood substitutes and perfusion solutions

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - calcium chloride dihydrate, quantity: 67.5 mg; sodium chloride, quantity: 1.5 g; sodium lactate, quantity: 792.5 mg; potassium chloride, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - compound sodium lactate (hartmann's) is used for intravenous fluid and electrolyte replacement, as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency and as a vehicle for intravenous drug delivery, if the drugs are compatible with the solutions.

United States - English - NLM (National Library of Medicine)

icu medical inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid, unspecified form - unii:33x04xa5at), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - this solution is indicated in patients requiring parenteral administration of potassium chloride and the replacement of extracellular losses of fluids and electrolytes with minimal carbohydrate calories. solutions containing potassium chloride are contraindicated in diseases where high potassium levels may be encountered. solutions containing lactate are not for use in the treatment of lactic acidosis. to open tear outer wrap at notch and remove solution container. if supplemental medication is desired, follow directions below before preparing for administration. some opacity of the plastic due to moisture absorption during the sterilization process may be observed. this is normal and does not affect the solution quality or safety. the opacity will diminish gradually. to add medication - prepare additive port. prepare additive port. - using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. using aseptic technique and an additive delivery needle of appropriate length, puncture resealable additive port at target area, inner diaphragm and inject. withdraw needle after injecting medication. - the additive port may be protected by covering with an additive cap. the additive port may be protected by covering with an additive cap. - mix container contents thoroughly. mix container contents thoroughly. preparation for administration (use aseptic technique) - close flow control clamp of administration set. close flow control clamp of administration set. - remove cover from outlet port at bottom of container. remove cover from outlet port at bottom of container. - insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. note: see full directions on administration set carton. insert piercing pin of administration set into port with a twisting motion until the set is firmly seated. note: see full directions on administration set carton. - suspend container from hanger. suspend container from hanger. - squeeze and release drip chamber to establish proper fluid level in chamber. squeeze and release drip chamber to establish proper fluid level in chamber. - open flow control clamp and clear air from set. close clamp. open flow control clamp and clear air from set. close clamp. - attach set to venipuncture device. if device is not indwelling, prime and make venipuncture. attach set to venipuncture device. if device is not indwelling, prime and make venipuncture. - regulate rate of administration with flow control clamp. regulate rate of administration with flow control clamp. warning: do not use flexible container in series connections.